Biopharmaceutical
Pharmaceutical
Health

Global Blood Therapeutics

$57.46
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.95 (1.68%) Today
$0.00 (0.00%) As of 3:46 PM EDT after-hours

Why Robinhood?

You can buy or sell GBT and other stocks, options, ETFs, and crypto commission-free!

About GBT

Global Blood Therapeutics, Inc. Common Stock, also called Global Blood Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Read More It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

Employees
171
Headquarters
South San Francisco, California
Founded
2011
Market Cap
3.18B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
692.38K
High Today
$57.54
Low Today
$56.33
Open Price
$56.59
Volume
435.79K
52 Week High
$64.94
52 Week Low
$30.15

Collections

Biopharmaceutical
Pharmaceutical
Health
Therapy
Biotechnology
Medical
Technology
2015 IPO

GBT Earnings

-$0.94
-$0.89
-$0.83
-$0.78
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.